Melissa B. Epperly, Director at Roivant Sciences Ltd. (ROIV), sold 17,750 shares at $36.08 ($641K) on 2026-10-01, disclosed to the SEC on 2026-10-05.
Scheduled sale ($641k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.08 | 16,850 | $608K | 94.9% |
| 2 | $36.57 | 900 | $33K | 5.1% |
| Total | $36.10 avg | 17,750 | $641K | 100% |
| Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $200K | — | Filing → |